Literature DB >> 10408808

Receptor-mediated transport of human amyloid beta-protein 1-40 and 1-42 at the blood-brain barrier.

J F Poduslo1, G L Curran, B Sanyal, D J Selkoe.   

Abstract

Since amyloid beta-protein (A beta) is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease, information regarding its permeability at the blood-brain barrier (BBB) will help elucidate the contribution of circulating A beta to vascular and parenchymal A beta deposition in this disease and in brain aging. The permeability of the D- and L-enantiomers of A beta 1-40 and L-A beta 1-42 at the BBB was determined in the normal adult rat by quantifying the permeability coefficient-surface area product (PS) for each protein after correction for the residual plasma volume (Vp) occupied by the protein [labeled with a different isotope of iodine (125I vs 131I)] in blood vessels of different brain regions. After a single i.v. bolus injection, the plasma pharmacokinetics determined by TCA precipitation, paper chromatography, and SDS-PAGE were similar for both 125I-L-A beta 1-40 and 125I-L-A beta 1-42. The PS at the BBB for L-A beta 1-42 was significantly (1.4- to 1.8-fold) higher than for L-A beta 1-40 and ranged from 17.7 to 26.4 x 10(-6) ml/g/s for different brain regions. A comparison of the PS values at the BBB for L-A beta 1-40 showed no significant difference when determined at 15 or 30 min after i.v. bolus injection, times that reflect different levels of degradation in plasma (37.9% at 15 min and 65.5% at 30 min). The PS values obtained, therefore, were representative of the intact protein rather than degradation products. The PS values obtained for the all-D-enantiomer of A beta 1-40 were very low and comparable to that of albumin and IgG, whose mechanism of transport is by passive diffusion. Taken together, these data imply a stereoisomer-specific, ligand-receptor interaction at the BBB for the L-A beta proteins. The high PS values observed for L-A beta 1-40 and 1-42 compare to insulin, whose uptake is decidedly by a receptor-mediated transport process, and suggest a similar mechanism for L-A beta entry into the brain.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10408808     DOI: 10.1006/nbdi.1999.0238

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  19 in total

1.  Macromolecules involved in production and metabolism of beta-amyloid at the brain barriers.

Authors:  Janelle S Crossgrove; Ellen L Smith; Wei Zheng
Journal:  Brain Res       Date:  2007-02-02       Impact factor: 3.252

2.  The protective role of DL-alpha-lipoic acid in the oxidative vulnerability triggered by Abeta-amyloid vaccination in mice.

Authors:  E Philip Jesudason; J Gunasingh Masilamoni; K Samuel Jesudoss; R Jayakumar
Journal:  Mol Cell Biochem       Date:  2005-02       Impact factor: 3.396

Review 3.  Western diet consumption and cognitive impairment: links to hippocampal dysfunction and obesity.

Authors:  Scott E Kanoski; Terry L Davidson
Journal:  Physiol Behav       Date:  2010-12-16

4.  Initial fate of prions upon peripheral infection: half-life, distribution, clearance, and tissue uptake.

Authors:  Akihiko Urayama; Rodrigo Morales; Michael L Niehoff; William A Banks; Claudio Soto
Journal:  FASEB J       Date:  2011-05-09       Impact factor: 5.191

5.  Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice.

Authors:  E M Sigurdsson; H Scholtzova; P D Mehta; B Frangione; T Wisniewski
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

Review 6.  Immunization treatment approaches in Alzheimer's and prion diseases.

Authors:  Thomas Wisniewski; Einar M Sigurdsson
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

7.  A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice.

Authors:  Marcin Sadowski; Joanna Pankiewicz; Henrieta Scholtzova; James A Ripellino; Yongsheng Li; Stephen D Schmidt; Paul M Mathews; John D Fryer; David M Holtzman; Einar M Sigurdsson; Thomas Wisniewski
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

Review 8.  Immunotherapy for Alzheimer's disease.

Authors:  David S Gelinas; Kevin DaSilva; Daniela Fenili; Peter St George-Hyslop; Joanne McLaurin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

9.  Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques.

Authors:  Joseph F Poduslo; Geoffry L Curran; Jane A Peterson; Daniel J McCormick; Abdul H Fauq; Murad A Khan; Thomas M Wengenack
Journal:  Biochemistry       Date:  2004-05-25       Impact factor: 3.162

Review 10.  Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies.

Authors:  Tamas Revesz; Janice L Holton; Tammaryn Lashley; Gordon Plant; Blas Frangione; Agueda Rostagno; Jorge Ghiso
Journal:  Acta Neuropathol       Date:  2009-02-19       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.